<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><submitter>Haldar T</submitter><funding>BLRD VA</funding><funding>NHLBI NIH HHS</funding><pubmed_abstract>&lt;h4>Background&lt;/h4>Polygenic risk scores derived from coronary artery disease genome-wide association studies are associated with statin relative risk reduction.&lt;h4>Objective&lt;/h4>Examine the relationship between coronary artery disease polygenic risk scores that include variants below thresholds of genome-wide significance and statin primary prevention of major adverse cardiovascular events.&lt;h4>Methods&lt;/h4>We generated coronary artery disease polygenic risk scores for participants with no past evidence of myocardial infarction from three electronic health record-linked genetic biobanks: All of Us Research Program, Genetic Epidemiology Research on Adult Health and Aging, and the Million Veteran Program. We scored each participant using three different polygenic risk scores: two with both ge</pubmed_abstract><journal>medRxiv : the preprint server for health sciences</journal><pagination>2025.10.09.25337698</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12633136</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Clinical validation of a statin-benefit polygenic score using real-world cohorts of primary prevention participants.</pubmed_title><pmcid>PMC12633136</pmcid><funding_grant_id>I01 BX003362</funding_grant_id><funding_grant_id>R56 HL161518</funding_grant_id><pubmed_authors>Risch N</pubmed_authors><pubmed_authors>Iribarren C</pubmed_authors><pubmed_authors>Toda N</pubmed_authors><pubmed_authors>Tsao PS</pubmed_authors><pubmed_authors>Voorhees AL</pubmed_authors><pubmed_authors>Popejoy AB</pubmed_authors><pubmed_authors>Iyer KR</pubmed_authors><pubmed_authors>Oni-Orisan A</pubmed_authors><pubmed_authors>Lu M</pubmed_authors><pubmed_authors>Douglas MP</pubmed_authors><pubmed_authors>Lynch JA</pubmed_authors><pubmed_authors>Najera JA</pubmed_authors><pubmed_authors>Tcheandjieu C</pubmed_authors><pubmed_authors>Chang KM</pubmed_authors><pubmed_authors>Lee KM</pubmed_authors><pubmed_authors>Haldar T</pubmed_authors><pubmed_authors>Bress A</pubmed_authors><pubmed_authors>Teerlink CC</pubmed_authors><pubmed_authors>Krauss RM</pubmed_authors></additional><is_claimable>false</is_claimable><name>Clinical validation of a statin-benefit polygenic score using real-world cohorts of primary prevention participants.</name><description>&lt;h4>Background&lt;/h4>Polygenic risk scores derived from coronary artery disease genome-wide association studies are associated with statin relative risk reduction.&lt;h4>Objective&lt;/h4>Examine the relationship between coronary artery disease polygenic risk scores that include variants below thresholds of genome-wide significance and statin primary prevention of major adverse cardiovascular events.&lt;h4>Methods&lt;/h4>We generated coronary artery disease polygenic risk scores for participants with no past evidence of myocardial infarction from three electronic health record-linked genetic biobanks: All of Us Research Program, Genetic Epidemiology Research on Adult Health and Aging, and the Million Veteran Program. We scored each participant using three different polygenic risk scores: two with both ge</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Oct</publication><modification>2026-06-01T03:11:22.525Z</modification><creation>2026-06-01T03:06:44.175Z</creation></dates><accession>S-EPMC12633136</accession><cross_references><pubmed>41282843</pubmed><doi>10.1101/2025.10.09.25337698</doi></cross_references></HashMap>